Effect of pathologic fractures on survival in multiple myeloma patients: a case control study

<p>Abstract</p> <p>Background</p> <p>Multiple Myeloma (MM) is a B cell neoplasm characterized by the clonal proliferation of plasma cells. Skeletal complications are found in up to 80% of myeloma patients at presentation and are major cause of morbidity.</p> <p>Methods</p> <p>49 patients were enrolled with MM admitted to Black Sea Technical University Hospital between 2002–2005. Pathologic fractures (PFs) were determined and the patients with or without PF were followed up minumum 3 years for survival analysis.</p> <p>Results</p> <p>PF was observed in 24 patients (49%) and not observed in 25 patients (51%). The risk of death was increased in the patients with PF compared with patients who had no fractures. While overall survival was 17.6 months in the patients with PFs, it was 57.3 months in the patients with no PFs.</p> <p>Conclusion</p> <p>These findings suggest that PFs may induce reduced survival and increased mortality in the MM patients, however, larger sample size is essential to draw clearer conclusions added to these data.</p

Lentiform fork sign in a diabetic uremic patient: pathophysiology is still not clear

50th Turkish National Neurology Congress -- NOV 21-27, 2014 -- Antalya, TURKEYWOS: 000484316100007Neurological disorders observed in end stage renal disease (ESRD) other than clouding of consciousness, involuntary movements and uremic encephalopathy capable of causing seizures include wakefulness defect caused by effects on basal ganglia associated with metabolic acidosis, movement disorder and, independent of these, progressive cognitive impairment of insidious onset. A 57-year-old male patient was started on hemodialysis (HD) with a diagnosis of ESRD secondary to diabetic nephropathy 5 months ago while under monitoring for diabetes mellitus and hypertension known for the previous 10 years. The patient presented to our hospital emergency service due to clouding of consciousness, wakefulness defect and lack of appetite that had begun 2 days ago. Computed tomography (CT) and diffusion magnetic resonance imaging (MRI) of the brain were performed during assessment in the emergency department. CT of the brain revealed symmetrical hypodensity in bilateral basal ganglia. Diffusion MRI of the brain revealed diffusion restriction not accompanied by hypointensity on apparent diffusion coefficient images in bilateral lentiform nucleus. Mannitol therapy was tapered and discontinued on day 3. The patient was enrolled on a 3-times-weekly HD program. Although the pathophysiology of lentiform fork sign (LFS) is still not fully clear, in our case, LFS may have developed due to insufficient dialysis and consequent metabolic acidosis and uremia. We report this case due to the rarity of LFS.Turkish Neurol So

Immunosuppressive Agents in the Treatment of Membranoproliferative Glomerulonephritis

INTRODUCTION: Treatment of membranoproliferative glomerulonephritis (MPGN) is often unrewarding with approximately 60% of patients progressing to end-stage renal failure within 10 years. In our study, we compared the efficacy of CS alone versus low dose CS + another immunosuppressive agent retrospectively. MATERIAL an

Outcome of Renal Transplantation in Patients With Diabetes Mellitus: A Single - Center Experience

WOS: 000491488703295

Elevated Resistin Levels are Associated with Inflammation in Hemodialysis Patients with Failed Renal Allografts

Background: Resistin is an adipocytokine, associated with insulin resistance and inflammation. The aim of this study is to evaluate the levels of serum resistin levels and other markers of inflammation in hemodialysis (HD) patients with failed renal allografts

Elevated resistin levels are associated with inflammation in hemodialysis patients with failed renal allografts

Background: Resistin is an adipocytokine, associated with insulin resistance and inflammation. The aim of this study is to evaluate the levels of serum resistin levels and other markers of inflammation in hemodialysis (HD) patients with failed renal allografts

Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients

Conversion from calcineurin inhibitor (CNI) to mTOR inhibitors may reduce and even halt the progression of chronic allograft dysfunction (CAD) which is the most important cause of renal allograft loss. We aimed to investigate the effects of conversion from CNI to everolimus on parameters of fibrosis, inflammation, glomerulotubular damage and vascular functions in renal transplant recipients